Summit Therapeutics Inc. Summit Therapeutics Inc.

Summit Therapeutics Inc.

SMMT

Clasificación en acciones #1702
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Precio por acción
$15.71
Última sincronización: 2026-10-19
Capitalización bursátil
$12.53B
Cambio (1 día)
7.35%
Cambio (1 año)
-21.63%
País
US
Comercio Summit Therapeutics Inc. (SMMT)

Categoría

Healthcare
Historial de dividendos de Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. (símbolo bursátil: SMMT) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Summit Therapeutics Inc. (SMMT) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL